Search results for " Cancer"

showing 10 items of 6120 documents

Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Agg…

2019

Breast cancer is a complex and heterogeneous disease: Several molecular alterations cause cell proliferation and the acquisition of an invasive phenotype. Extracellular matrix (ECM) is considered essential for sustaining tumor growth and matrix metalloproteinases (MMPs) have been identified as drivers of many aspects of the tumor phenotype. Mounting evidence indicates that both &alpha

0301 basic medicineAlpha-enolaseENO1Kaplan-Meier EstimateMatrix metalloproteinasemedicine.disease_causeMetastasisExtracellular matrixlcsh:Chemistry0302 clinical medicineSettore BIO/06 - Anatomia Comparata E Citologialcsh:QH301-705.5SpectroscopybiologyMMP-2General MedicineComputer Science ApplicationsDNA-Binding ProteinsGene Expression Regulation NeoplasticMatrix Metalloproteinase 9030220 oncology & carcinogenesisDisease ProgressionMatrix Metalloproteinase 2FemaleMMP-9Breast NeoplasmsCatalysisArticleInorganic Chemistry03 medical and health sciencesBreast cancerbreast cancerCell Line TumormedicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMBP-1Molecular BiologyCell ProliferationTumor Suppressor ProteinsOrganic ChemistryCancermedicine.diseaseSettore BIO/18 - Genetica030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Phosphopyruvate HydrataseCancer cellbiology.proteinCancer researchCarcinogenesisInternational Journal of Molecular Sciences
researchProduct

Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer

2019

Background:Vascular endothelial growth factor (VEGF)-C, -D, and VEGF receptor-3 are proteins characterized as crucial for tumor lymphangiogenesis. It is accompanied by angiogenesis during wound healing, but also in the neoplastic process. The research studies have shown that the lymphatic system plays a key role in the progression of carcinogenesis.Objective:The aim of this study was to evaluate changes in the expression of VEGF-C, VEGF-D and VEGFR-3 in different grades of endometrial cancer (G1-G3).Methods:The study included 45 patients diagnosed with endometrial cancer (G1=17; G2=15; G3=13) and 15 patients without neoplastic changes. The expression of VEGF-C, VEGF-D, and VEGFR-3 was asses…

0301 basic medicineAngiogenesisVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DVEGF-CPharmaceutical ScienceVEGF-Dmedicine.disease_causeMetastasisTranscriptome03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansANOVANeovascularization Pathologicbusiness.industryEndometrial cancerCancerVascular Endothelial Growth Factor Receptor-3medicine.diseaseImmunohistochemistryEndometrial NeoplasmsLymphangiogenesisVEGFR-3lymphangiogenesisVascular endothelial growth factor030104 developmental biologychemistry030220 oncology & carcinogenesisendometrial cancerCancer researchFemaleNeoplasm GradingCarcinogenesisbusinessBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors

2016

Angiogenesis is a key moment in tumor development and proliferation. Until recently oncologists did not know the mechanisms that were behind this phenomenon, but following the discoveries of Folkman and coworkers, they have gradually created and developed a series of drugs that act against angiogenesis by interacting with molecules belonging to the vascular endothelial growth factor (VEGFs) class and its receptors (VEGFRs) giving rise to anticancer effects. Tyrosine kinase inhibitors (TKIs) are a major class of these new anticancer agents, demonstrating high antitumor activity in a variety of "orphan" neoplasms (such as hepatocellular carcinoma, kidney cancer, sarcomas, etc.). The mechanism…

0301 basic medicineAngiogenesis; Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; VEGF; VEGF pathway; Medicine (all)Settore MED/06 - Oncologia MedicaAngiogenesisTyrosine kinase inhibitorPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVEGF pathwaymedicineReceptorCardiotoxicitybusiness.industryMedicine (all)medicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorAngiogenesiCardio-oncology030104 developmental biologyMechanism of actionchemistry030220 oncology & carcinogenesisHepatocellular carcinomamedicine.symptombusinessKidney cancerTyrosine kinase
researchProduct

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

2016

// Daniele Fanale 1, * , Valeria Amodeo 1, * , Viviana Bazan 1, * , Lavinia Insalaco 1 , Lorena Incorvaia 1 , Nadia Barraco 1 , Marta Castiglia 1 , Sergio Rizzo 1 , Daniele Santini 2 , Antonio Giordano 3 , Sergio Castorina 4, 5, # , Antonio Russo 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 4 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 5 Department of Biomedic…

0301 basic medicineAntineoplastic AgentsBreast NeoplasmsBioinformatics03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancermicroRNAmedicineHumansZoledronic acidPI3K/AKT/mTOR pathwaybone metastasisBone Density Conservation AgentsDiphosphonatesMicroarray analysibusiness.industryGene Expression ProfilingImidazolesBone metastasisMicroRNA Expression Profilemedicine.diseaseActin cytoskeletonMolecular medicineBone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid; Oncology030104 developmental biologyZoledronic acidOncologyBone metastasi030220 oncology & carcinogenesisMCF-7 CellsCancer researchmiRNA expression profilemicroarray analysisTranscriptomebusinessResearch Papermedicine.drug
researchProduct

Antiproliferative Effect of Bioaccessible Fractions of Four Brassicaceae Microgreens on Human Colon Cancer Cells Linked to Their Phytochemical Compos…

2020

The antiproliferative effect of the bioaccessible fractions (BFs) of four hydroponic Brassicaceae microgreens (broccoli, kale, mustard and radish) was evaluated on colon cancer Caco-2 cells vs. normal colon CCD18-Co cells after 24 h treatment with BFs diluted 1:10 v/v in cell culture medium. Their bioactivity was compared with the digestion blank, while the colon cancer chemotherapeutic drug 5-fluorouracil was used as a positive control. Cell viability (mitochondrial enzyme activity assay (MTT test) and Trypan blue test) and mechanisms related to antiproliferative activity (cell cycle, apoptosis/necrosis, mitochondrial membrane potential, reactive oxygen species (ROS) production, Ca2+ and g…

0301 basic medicineAntioxidantPhysiologymedicine.medical_treatmentClinical BiochemistryBrassicaPharmacologyBiochemistryArticle03 medical and health scienceschemistry.chemical_compoundmedicineViability assayCaco-2 cellsMolecular Biologychemistry.chemical_classificationReactive oxygen species030109 nutrition & dieteticsMicrogreenslcsh:RM1-950bioaccessible fractionsCell BiologyGlutathioneAscorbic acidMicrogreen030104 developmental biologylcsh:Therapeutics. Pharmacologyantiproliferative effectchemistrycolon cancerApoptosis<i>Brassica</i>Trypan blueAntioxidants
researchProduct

Green Tea Catechins Induce Inhibition of PTP1B Phosphatase in Breast Cancer Cells with Potent Anti-Cancer Properties: In Vitro Assay, Molecular Docki…

2020

The catechins derived from green tea possess antioxidant activity and may have a potentially anticancer effect. PTP1B is tyrosine phosphatase that is oxidative stress regulated and is involved with prooncogenic pathways leading to the formation of a.o. breast cancer. Here, we present the effect of selected green tea catechins on enzymatic activity of PTP1B phosphatase and viability of MCF-7 breast cancer cells. We showed also the computational analysis of the most effective catechin binding with a PTP1B molecule. We observed that epigallocatechin, epigallocatechin gallate, epicatechin, and epicatechin gallate may decrease enzymatic activity of PTP1B phosphatase and viability of MCF-7 cells.…

0301 basic medicineAntioxidantPhysiologymedicine.medical_treatmentClinical BiochemistryPhosphataseProtein tyrosine phosphataseEpigallocatechin gallateBiochemistrycomplex mixturesArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinebreast cancermedicineheterocyclic compoundsViability assayMolecular Biologyepigallocatechinprotein tyrosine phosphatase inhibitorChemistrylcsh:RM1-950food and beveragesPTP1BCell BiologyCatechin bindingIn vitro030104 developmental biologyEpicatechin gallatelcsh:Therapeutics. PharmacologyBiochemistrySettore CHIM/03 - Chimica Generale E Inorganica030220 oncology & carcinogenesissense organshormones hormone substitutes and hormone antagonistsgreen tea catechinsAntioxidants
researchProduct

Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopaus…

2019

Introduction Glucose 6-phosphate dehydrogenase (G6PD) is a basic antioxidant pathway for erythrocytes, being its deficiency the most common gene mutation worldwide. As breast cancer is one of the most frequent tumors, many of these patients may present with G6PD deficiency prior treatment without notice. Case report We present the case of a woman deficient for G6PD with the diagnosis of Stage IIIB (cT4d cN1 cM0) HER2-enriched early breast cancer. Management and outcome The patient underwent neoadjuvance with trastuzumab and anthracycline-free chemotherapy, based on docetaxel (75 mg/m2, 120 mg) and carboplatin (AUC 5, 560 mg). She did not present hemolytic crisis and no blood transfusions we…

0301 basic medicineAntioxidantReceptor ErbB-2medicine.medical_treatmentCommon geneBreast NeoplasmsDehydrogenasemedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabmedicineHumansGlucose-6-phosphate dehydrogenasePharmacology (medical)skin and connective tissue diseasesAgedEarly breast cancerMutationbusiness.industryTrastuzumabmedicine.diseaseNeoadjuvant TherapyPostmenopauseGlucosephosphate Dehydrogenase DeficiencyTreatment Outcome030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisCancer researchFemalebusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II …

2016

e20522Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation may contribute to primary and secondary resistance to platinum (Pt)-based chemotherapy (CT) in sqNSCLC. The pan-PI3K inhibi...

0301 basic medicineBasaltCancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentBuparlisib03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisSquamous non-small cell lung cancerCancer researchmedicinePhosphatidylinositolbusinessPI3K/AKT/mTOR pathwayJournal of Clinical Oncology
researchProduct

Oxidative stress and antioxidants in the pathophysiology of malignant melanoma.

2018

Abstract The high number of somatic mutations in the melanoma genome associated with cumulative ultra violet (UV) exposure has rendered it one of the most difficult of cancers to treat. With new treatment approaches based on targeted and immune therapies, drug resistance has appeared as a consistent problem. Redox biology, including reactive oxygen and nitrogen species (ROS and RNS), plays a central role in all aspects of melanoma pathophysiology, from initiation to progression and to metastatic cells. The involvement of melanin production and UV radiation in ROS/RNS generation has rendered the melanocytic lineage a unique system for studying redox biology. Overall, an elevated oxidative st…

0301 basic medicineBiochemistry & Molecular BiologyClinical Biochemistrymedicine.disease_causeBiochemistryAntioxidantsMelanin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedicineAnimalsHumanstumor microenvironmentEpigeneticsmetastasesMolecular BiologyMelanomaReactive nitrogen specieschemistry.chemical_classificationreactive oxygen speciesReactive oxygen speciesTumor microenvironmentskin cancerbusiness.industryMelanomaintracellular redox statemedicine.diseaseOxidative Stress030104 developmental biologyreactive nitrogen specieschemistry030220 oncology & carcinogenesisCancer researchBiochemistry and Cell BiologySkin cancerbusinessOxidation-ReductionOxidative stressSignal Transduction
researchProduct

Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients

2021

Summary A 12-month exercise program reversibly prevented hip bone loss in premenopausal women with early breast cancer. The bone-protective effect was maintained for 2 years after the end of the program but was lost thereafter. Purpose Breast cancer survivors are at an increased risk for osteoporosis and fracture. This 5-year follow-up of a randomized impact exercise intervention trial evaluated the maintenance of training effects on bone among breast cancer patients. Methods Five hundred seventy-three early breast cancer patients aged 35–68 years and treated with adjuvant therapy were allocated into a 12-month exercise program or a control group. Four hundred forty-four patients (77%) were…

0301 basic medicineBone densityEndocrinology Diabetes and MetabolismOsteoporosisphysical activityliikuntaweight-bearing impact aerobic exerciseMetabolic equivalent0302 clinical medicineAbsorptiometry PhotonBreast cancerBone DensityMedicineharjoitteluSURVIVORSRISKBone mineraltrainingrintasyöpäFemur Neckbone densityCHEMOTHERAPYMiddle Aged3. Good healthmedicine.anatomical_structurePOSTMENOPAUSAL WOMENTRIALFemaleOriginal ArticleHEALTHfyysinen aktiivisuusAdultmedicine.medical_specialtyBODY-COMPOSITIONgovernment.form_of_governmentosteoporoosi3122 CancersluuntiheysEXERCISE030209 endocrinology & metabolismBreast NeoplasmsMASSStep aerobics03 medical and health sciencesBreast cancerbreast cancerInternal medicineAdjuvant therapyHumansTrainingFemoral neckAgedbusiness.industryPhysical activitymedicine.diseaseaerobinen harjoitteluosteoporosisgovernmentOsteoporosisWeight-bearing impact aerobic exercise030101 anatomy & morphologyPHYSICAL PERFORMANCEbusinessFollow-Up Studies
researchProduct